Ender Salbaş, Faruk Özşahin, Mustafa Canbaz, Sertaç Ketenci

Romatoloji Kliniğindeki Ender Bir İnterstisyel Akciğer Hastalığı Sebebi: Sulfasalazinin Tetiklediği Akut Akciğer Hasarı Olgusu

Enfeksiyon, primer akciğer hastalıkları, romatolojik tutulum, malignite ve ilaca bağlı tutulumların hepsi interstisyel akciğer hastalığı bulgularıyla acil servise başvuran bir romatizma hastasında akla gelebilecek ayırıcı tanılardır. İlaçlara bağlı tutulumlar tüm interstisyel akciğer hastalığı olgularının %2.5 -3 arasındaki sebebini oluşturur. Sülfasalazin inflamatuar romatolojik hastalıkların tedavisinde geniş kullanım alanı olan bir ajan olup interstiyel akciğer hastalıklarına oldukça seyrek de olsa sebep olabilmektedir. Ayrıca sülfasalazine bağlı akciğer tutulumu enfeksiyonlar ve romatolojik tutulumları da taklit edip ciddi tanısal karışıklığa sebep olabilir. Bu yazımızda, nadiren karşılaşılan sülfasalazinin tetiklediği akciğer olgumuz ve bu durumun tedavisine değindik.

A rare cause of interstitial lung disease in rheumatology clinic: case report for sulfasalazine-induced acute pulmonary injury

Infection, primary lung pathology, rheumatic involvement, malignancy and druginduced involvement can be suggested as differential diagnosis of a case with rheumatic disease ,who applied to an emergency service with pulmonary symptoms. The drugs cause 2.5-3% of all interstitial lung diseases. Sulfasalazine has been widely used in the treatment of inflammatory rheumatic conditions and it is an extremely rare reason for interstitial lung disase. Here, we aimed to present the rarely seen sulfasalazine-induced interstitial pulmonary disease and its treatment. Sulphasalazine-induced lung disease can mimic the symptoms of infectious and rheumatic lung involvement, and can cause serious diagnostic confusion.

PDF

___

1. F.A. Fagan LN, Malesker MA, Morrow EL. , Therapeutic update on Drug-Induced pulmonary disorders, US Pharm. (2011) 36(7):HS3-HS8. https://www.uspharmacist.com/ article/therapeutic-update-on-drug-induced-pulmonary-disorders
2. D.B. Coultas, R.E. Zumwalt, W.C. Black, et al., The epidemiology of interstitial lung diseases, Am J Respir Crit Care Med 150(4) (1994) 967-72. https://doi.org/10.1164/ ajrccm.150.4.7921471
3. S. American Thoracic, S. European Respiratory, American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001, Am J Respir Crit Care Med 165(2) (2002) 277-304. https://doi.org/10.1164/ajrccm.165.2.ats01
4. G. Raghu, F. Nyberg, G. Morgan, The epidemiology of interstitial lung disease and its association with lung cancer, Br J Cancer 91 Suppl 2 (2004) S3-10. https://doi. org/10.1038/sj.bjc.6602061
5. B. Bradley, H.M. Branley, J.J. Egan, et al., Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society, Thorax 63 Suppl 5 (2008) v1-58. https://doi. org/10.1136/thx.2008.101691
6. O. Matsuno, Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches, Respir Res 13 (2012) 39. https://doi.org/10.1186/1465-9921-13-39
7. M. Momeni, N. Taylor, M. Tehrani, Cardiopulmonary manifestations of ankylosing spondylitis, Int J Rheumatol 2011 (2011) 728471. https://doi.org/10.1155/2011/728471
8. M. Schwaiblmair, W. Behr, T. Haeckel, et al., Drug induced interstitial lung disease, Open Respir Med J 6 (2012) 63-74. https://doi.org/10.2174/1874306401206010063
9. S. Skeoch, N. Weatherley, A.J. Swift, et al., Drug-Induced Interstitial Lung Disease: A Systematic Review, J Clin Med 7(10) (2018). https://doi.org/10.3390/jcm7100356
10. G. Bahat, H.G. Celik, F. Tufan, et al., Drug rash with eosinophilia and systemic symptoms syndrome induced by sulfasalazine, Joint Bone Spine 77(1) (2010) 87-8. https:// doi.org/10.1016/j.jbspin.2009.08.003
11. G.R. Mohyuddin, F. Sultan, K. Zhang, et al., Sulfasalazine induced lung toxicity masquerading as sarcoidosis--case report and review of the literature, Sarcoidosis Vasc Diffuse Lung Dis 30(3) (2013) 226-30. https://www.ncbi.nlm.nih.gov/pubmed/24284297
12. S.D. Parry, C. Barbatzas, E.T. Peel, et al., Sulphasalazine and lung toxicity, Eur Respir J 19(4) (2002) 756-64. https://doi.org/10.1183/09031936.02.00267402
13. P. Nadarajan, A. Fabre, E. Kelly, Sulfasalazine: A rare cause of acute eosinophilic pneumonia, Respir Med Case Rep 18 (2016) 35-6. https://doi.org/10.1016/j. rmcr.2016.03.006
14. N. Miura, R. Aoyama, W. Kitagawa, et al., Proteinase 3-antineutrophil cytoplasmic antibody-(PR3-ANCA) positive necrotizing glomerulonephritis after restarting sulphasalazine treatment, Clin Nephrol 71(1) (2009) 74-9. https://doi.org/10.5414/cnp71074